Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00077142

TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

Phase I/II Dose Escalation, Pharmacokinetic, Safety, and Efficacy Study of Oral TAC-101 in Patients With Advanced Hepatocellular Carcinoma

Sponsor: M.D. Anderson Cancer Center

Conditions Liver Cancer

Interventions TAC-101

Updated 6 times since 2017 Last updated: Oct 30, 2018 Started: Apr 30, 2001 Primary completion: Jul 31, 2005 Completion: Aug 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Liver Cancer and is currently completed. M.D. Anderson Cancer Center leads this study, which shows 6 recorded versions since 2001 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Nov 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Nov 2018 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Apr 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Taiho Pharmaceutical Co., Ltd.

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States